Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention (STATUS PCI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01464671 |
Recruitment Status
:
Terminated
(DSMB halted the study early due to futility. There were no safety concerns.)
First Posted
: November 3, 2011
Last Update Posted
: November 20, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The objective of the study is to assess the safety and efficacy of Angiomax® (bivalirudin) versus unfractionated heparin (UFH) in patients presenting with stable angina or silent ischemia (positive stress test without chest pain) that undergo percutaneous coronary intervention (PCI).
The primary endpoint of the study will be major and minor bleeding events, defined by the REPLACE-2 trial definition, during the index hospitalization and up to 30 days post discharge.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Artery Disease | Drug: Bivalirudin Drug: Heparin | Phase 4 |
The purpose of this study is to compare in a randomized, controlled, single-blinded, 1:1 fashion UFH versus bivalirudin in patients with stable angina pectoris or silent ischemia undergoing PCI.
Secondary study endpoints will include:
- Major adverse cardiac events (MACE) comprising of all cause mortality, myocardial infarction (MI), ischemia driven target vessel revascularization (TVR), and cerebral vascular accident (CVA).
- Net adverse clinical events (NACE) will be consistent of MACE plus major bleeding as defined by the REPLCE-2 criteria.
- Cardiac death in-hospital and up to 30 days post discharge.
- MI in-hospital and up to 30 days post discharge.
- CVA in-hospital and up to 30 days post discharge.
- Incidence of all-cause mortality at 6 months and 1 year.
- MACE at 6 months and 1 year.
- Incidence of acute (0-24 hours post procedure) stent thrombosis rates.
- Incidence of sub-acute (24 hours - 30 days) stent thrombosis rates.
- Length of hospital stay (LOS)
- Economic analysis (total cost during hospitalization) and up to 30 days post discharge.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 260 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | STATUS-PCI: Stable Angina Therapy With Angiomax® or Unfractionated Heparin for patientS Undergoing Percutaneous Coronary Intervention |
Study Start Date : | July 2009 |
Actual Primary Completion Date : | September 2014 |
Actual Study Completion Date : | September 2014 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Bivalirudin
Anticoagulation during percutaneous coronary intervention
|
Drug: Bivalirudin
Anticoagulation during percutaneous coronary intervention
Other Name: Angiomax
Drug: Heparin
Anticoagulation during percutaneous coronary intervention
|
Active Comparator: Unfractionated Heparin
Anticoagulation during percutaneous coronary intervention
|
Drug: Heparin
Anticoagulation during percutaneous coronary intervention
|
- Bleeding events [ Time Frame: 30 days ]The primary endpoint of the study will be major and minor bleeding events, defined by the REPLACE-2 trial definition during the index hospitalization and up to 30 days post discharge.
- MACE [ Time Frame: 1 year ]Major adverse cardiac events (MACE) comprising of all cause mortality, myocardial infarction (MI), ischemia driven target vessel revascularization (TVR), and cerebral vascular accident (CVA).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The patient is male or female ≥ 18 years of age.
- The patient presents with stable angina pectoris, or silent ischemia (positive stress test without chest pain).
- The patient is scheduled for coronary angiography, with possible angioplasty.
- The patient is able to tolerate dual anti-platelet therapy with aspirin and clopidogrel for a minimum of 30 days and is on those medications at the time of the PCI (clopidogrel may be administered during PCI or within 30 minutes post PCI).
- The patient is able and willing to conform to the requirements of the study and voluntarily signs an Informed Consent.
- The patient does not present with any form of illness or condition that in the investigator's opinion would impair the results of the study.
- Women of child bearing potential must have a negative urine or serum pregnancy test prior to enrollment.
Exclusion Criteria:
- Patients in cardiogenic shock.
- Patients with acute coronary syndrome, which includes unstable angina, non-ST-elevation MI or STEMI.
- Known history of heparin-induced thrombocytopenia.
- Contraindication to unfractionated heparin, bivalirudin, or any anticoagulant or antithrombotic pharmacological agent.
- Any significant medical condition, which in the investigator's opinion, may interfere with the patient's optimal participation in the study.
- Pregnant women or nursing mothers.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01464671
United States, New York | |
Stony Brook University Medical Center | |
Stony Brook, New York, United States, 11794 |
Principal Investigator: | Allen Jeremias, MD | Stony Brook University |
Responsible Party: | Allen Jeremias, Associate Professor, Stony Brook University |
ClinicalTrials.gov Identifier: | NCT01464671 History of Changes |
Other Study ID Numbers: |
119778 (IRB ID) |
First Posted: | November 3, 2011 Key Record Dates |
Last Update Posted: | November 20, 2014 |
Last Verified: | November 2014 |
Keywords provided by Allen Jeremias, Stony Brook University:
Coronary Artery Disease Stable Angina Percutaneous Coronary Intervention |
Additional relevant MeSH terms:
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Calcium heparin Bivalirudin |
Heparin Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors |